Choline

Overview

A basic constituent of lecithin that is found in many plants and animal organs. It is important as a precursor of acetylcholine, as a methyl donor in various metabolic processes, and in lipid metabolism.

Indication

For nutritional supplementation, also for treating dietary shortage or imbalance

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Comparison of the Effects of Oral Ulceration Healing in Patients Wearing a Removable Denture	2024/08/01	NCT06531720	Not Applicable	Completed	Medical University of Silesia
Choline and Iron Deficiency	2024/07/30	NCT06527391	Phase 2	Recruiting	University of Minnesota
Maternal Choline Supplementation and Cannabis Use During Pregnancy: Impact on Early Brain Development	2024/04/23	NCT06379971	Phase 1	Recruiting	University of Colorado, Denver
Effects of a Nutraceutic Compound on Cognitive Impairment	2024/01/11	NCT06200883	Phase 4	Completed	Federico II University
Choline Effects - Pre-symptomatic AD	2023/05/30	NCT05880849	Phase 1	Recruiting	Paul E Schulz
Efficacy and Safety of ChOline ALfoscerate in Patient With Mild to Moderate Alzheimer's Disease	2022/05/20	NCT05383183	Phase 4	Recruiting	Daewoong Bio Inc.
Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia	2022/05/09	NCT05365425	Phase 4	Recruiting	Seoul National University Bundang Hospital
Choline Supplementation as a Neurodevelopmental Intervention in Fetal Alcohol Spectrum Disorders Study	2021/11/05	NCT05108974	Phase 2	Active, not recruiting	Jeff Wozniak
Reverse Triple Negative Immune Resistant Breast Cancer	2021/10/13	NCT05076682	Phase 2	Recruiting	Fudan University
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Vascular Cognitive Impairment Patients	2021/09/20	NCT05050604	Phase 4	Not yet recruiting	Chong Kun Dang Pharmaceutical

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
Livita Children	PureTek Corporation	59088-660	ORAL	66.67 mg in 1 mL	12/18/2023
Fenofibric acid	A-S Medication Solutions	50090-4373	ORAL	135 mg in 1 1	5/1/2019
Prenatrix	PureTek Corporation	59088-166	ORAL	55 mg in 1 1	2/8/2023
Lipovite	Perdido Key Health and Wellness Inc	70104-128	INTRAMUSCULAR	1 mg in 1 mL	11/23/2015
Fenofibric Acid Delayed-Release	TWi Pharmaceuticals, Inc.	24979-112	ORAL	135 mg in 1 1	3/25/2020
Livita Adults	PureTek Corporation	59088-659	ORAL	200 mg in 1 mL	12/18/2023
Fenofibric acid	Macleods Pharmaceuticals Limited	33342-295	ORAL	135 mg in 1 1	2/26/2024
Fenofibric acid	Lupin Pharmaceuticals, Inc.	68180-128	ORAL	45 mg in 1 1	12/8/2023
Fenofibric Acid Delayed-Release	TWi Pharmaceuticals, Inc.	24979-109	ORAL	45 mg in 1 1	3/25/2020
Prenatryl	PureTek Corporation	59088-169	ORAL	55 mg in 1 1	2/8/2023

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
Super B Complex tablets	126510	Sphere Healthcare Pty Ltd	Medicine	A	3/28/2006
Wealthy Health Bio-Maxi B Excellent Stress Relief Formula with Herbs	139048	Universal Pharmaceuticals Pty Ltd	Medicine	A	5/21/2007
Lifetime Brain Q	297835	Lifetime Pharmaceuticals	Medicine	A	12/20/2017
IND/HK/SG SWISSE ULTIBOOST LIVER DETOX	329086	Swisse Wellness Pty Ltd	Medicine	A	1/22/2020
Threshold Controlled B-Complex	276600	NeoLife International Pty Ltd	Medicine	A	6/15/2016
Mediherb P2-Detox	218993	Integria Healthcare Australia Pty Ltd	Medicine	A	1/8/2014
Visdon BRAINBOOK Concentration Support	371690	Visdon Pty Ltd	Medicine	A	7/27/2021
Swisse Ultiboost Magnesium + Sleep Powder	313001	Swisse Wellness Pty Ltd	Medicine	A	1/8/2019
MUSASHI SLEEP RECOVERY	308710	Vitaco Health Australia Pty Ltd	Medicine	A	8/28/2018
DHA BABY BRAIN BUILDER	318347	Pharmacare Laboratories Pty Ltd	Medicine	A	6/4/2019

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
STRESS B CAPSULES WITH VITAMIN C	rheingold food international ltd.	00694509	Capsule - Oral	25 MG / CAP	12/31/1987
STRESS B WITH 1000 MG VITAMIN C	holista health (canada) inc.	02246252	Tablet - Oral	25 MG	11/13/2002
LIQUI B COMPLEX PLUS	twin laboratories inc.	01984411	Liquid - Oral	10 MG / ML	12/31/1995
MATERNITY ONE MULTIVITAMIN WITH MINS CAPLET	swiss herbal remedies ltd.	01918052	Tablet - Oral	25 MG	12/31/1991
GLYCO LITE ECT	dynamic nutritional associates	00548987	Tablet (Enteric-Coated) - Oral	33 MG	12/31/1981
FORMULA 22158	therapeutic foods co.	00191531	Capsule - Oral	9 MG / CAP	5/18/1994
TWIN PRO POWDER VANILLA	twin laboratories inc.	02014149	Powder - Oral	25 MG / 71.35 G	12/31/1995
WOMEN'S 45+	natural factors nutritional products ltd.	02244128	Tablet - Oral	16.7 MG	12/19/2001
ONE PER DAY OMNIPLEX WITH BETA CAROTENE-TAB	vita health products inc	02135795	Tablet - Oral	15 MG	10/11/1996
MULTI-FORCE FOR ADULTS TAB	bioforce canada inc.	02009439	Tablet - Oral	150 MG / TAB	12/31/1994

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

Protara Therapeutics Announces Key Milestones for 2025, Including NMIBC and LM Data

8 months ago

Protara Therapeutics anticipates mid-2025 data from the ADVANCED-2 trial of TARA-002 in non-muscle invasive bladder cancer (NMIBC) patients, building on positive six-month results.

Research Error Sparks Unwarranted Concerns Over Heavy Metal Content in Prenatal Vitamins